Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of oral panobinostat in adults with relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant and gemcitabine/vinorelbine/vinblastine-based regimen failure
2008-003016-35Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panobinostat in Hodgkin lymphoma (HL), sponsored by Novartis. Primary endpoints: Objective response rate by CT/MRI and Radiologic monitoring for progression. Started Jul 2008; status: completed.
02
Drugs
panobinostat
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on 2008-003016-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003016-35.